LPRO ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Open Lending Corporation - June 30, 2025 Deadline — Neutral
LPRO Accesswire — June 02, 2025NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Open Lending Corporation (NASDAQ:LPRO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/open-lending-corporation-lawsuit-submission-form?prid=151293&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq.

Expanding Access: More PG&E Customers Eligible for 18% Electric Discount Under New Support Program Guidelines — Neutral
PCG PRNewsWire — June 02, 2025Customers are Encouraged to Check Eligibility and Apply for Monthly Electric Discount OAKLAND, Calif. , June 2, 2025 /PRNewswire/ -- More than an estimated 150,000 additional Pacific Gas and Electric Company (PG&E) customers are now eligible for an 18% discount on their electric rate.

Securities Fraud Class Action Filed Against Ibotta, Inc. (IBTA) - Levi & Korsinsky Reminds Investors of June 16, 2025 — Neutral
IBTA Accesswire — June 02, 2025NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Ibotta, Inc. (NYSE:IBTA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ibotta-lawsuit-submission-form?prid=151289&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq.

Lost Money on Organon & Co. (OGN)? Contact Levi & Korsinsky Before July 22, 2025 to Join Class Action — Neutral
OGN Accesswire — June 02, 2025NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151295&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.

Did You Lose Money on Civitas Resources, Inc. (CIVI)? Levi & Korsinsky Urges Investors to Act Before July 1, 2025 — Neutral
CIVI Accesswire — June 02, 2025NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Civitas Resources, Inc. (NYSE:CIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/civitas-resources-lawsuit-submission-form?prid=151296&wire=1&utm_campaign=28 or contact Joseph E. Levi, Esq.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Krispy Kreme, Inc. of Class Action Lawsuit and Upcoming Deadlines - DNUT — Neutral
DNUT GlobeNewsWire — June 02, 2025NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Krispy Kreme, Inc. (“Krispy Kreme” or the “Company”) (NASDAQ: DNUT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Canopy Growth Corporation (CGC) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of June 3, 2025 Deadline — Neutral
CGC Accesswire — June 02, 2025NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Canopy Growth Corporation (NASDAQ:CGC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/canopy-growth-corporation-lawsuit-submission-form?prid=151292&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Companies, Inc. of Class Action Lawsuit and Upcoming Deadlines - RKT — Neutral
RKT GlobeNewsWire — June 02, 2025NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit is pending against Rocket Companies, Inc. (“Rocket Companies” or the “Company”) (NYSE: RKT). Investors in Rocket Companies securities are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Watts Water Stock Rises 26% in a Year: Will the Uptrend Continue? — Positive
WTS Zacks Investment Research — June 02, 2025WTS rides a 26% stock surge with strong M&A moves, new tech and margin gains despite weak Europe sales.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA — Neutral
IOVA GlobeNewsWire — June 02, 2025NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ibotta — Neutral
IBTA GlobeNewsWire — June 02, 2025Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ibotta To Contact Him Directly To Discuss Their Options

AdaptHealth At A Crossroads: Automation, Integration, And The Future Of Home Care — Negative
AHCO Seeking Alpha — June 02, 2025AdaptHealth's national scale and AI-driven efficiencies position it well for value-based contracts, aiming to curb hospital readmissions and improve EBITDA margins. The company faces potential risks from competitive-bidding discounts, unresolved litigation, and execution challenges on the One Adapt ERP migration. Management's 2025 guidance suggests flat organic revenue and a 21% EBITDA margin, with shares appearing undervalued compared to peers.

Investors Urged to Contact Levi & Korsinsky for Information Before July 7, 2025 - West Pharmaceutical Services, Inc. (WST) — Neutral
WST Accesswire — June 02, 2025NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your West Pharmaceutical Services, Inc. (NYSE:WST) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=151287&wire=1&utm_campaign=5 or contact Joseph E. Levi, Esq.

Securities Fraud Class Action Filed Against DoubleVerify Holdings, Inc. (DV) - Levi & Korsinsky Reminds Investors of July 21, 2025 — Neutral
DV Accesswire — June 02, 2025NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your DoubleVerify Holdings, Inc. (NYSE:DV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/doubleverify-holdings-inc-lawsuit-submission-form-2?prid=151286&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Digimarc Corporation of Class Action Lawsuit and Upcoming Deadlines - DMRC — Neutral
DMRC GlobeNewsWire — June 02, 2025NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Digimarc Corporation (“Digimarc” or the “Company”) (NASDAQ: DMRC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

SelectQuote, Inc. Investor News: If You Have Suffered Losses in SelectQuote, Inc. (NYSE: SLQT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights — Neutral
SLQT GlobeNewsWire — June 02, 2025NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of SelectQuote, Inc. (NYSE: SLQT) resulting from allegations that SelectQuote may have issued materially misleading business information to the investing public.

Boeing CEO Ortberg is winning hearts on Wall Street. Here's the latest vote of confidence. — Positive
BA Market Watch — June 02, 2025Boeing's stock could rise 25%, BofA analysts said, as the aerospace and defense giant works to break out of its “doom loop.”

Google to spend $500M to revamp compliance structure after shareholders seek ‘culture change' — Neutral
GOOG GOOGL New York Post — June 02, 2025Shareholders led by two Michigan pension funds accused Google executives and directors of breaching their fiduciary duties by exposing the company to antitrust liability related to its search, Ad Tech, Android and app distribution businesses.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UnitedHealth Group Incorporated of Class Action Lawsuit and Upcoming Deadlines - UNH — Neutral
UNH GlobeNewsWire — June 02, 2025NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against UnitedHealth Group Incorporated (“UnitedHealth” or the “Company”) (NYSE: UNH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech — Positive
BMY BNTX CNBC Television — June 02, 2025Christopher Boerner, CEO of Bristol Myers Squibb, said Monday that the company's $11 billion cancer drug partnership with BioNTech could be "the next new frontier in the treatment of cancer." The companies will work on transforming outcomes for patients with difficult-to-treat solid tumors, Boerner said.
